References
  1. Connor TH, MacKenzie BA, DeBord DG, et al. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016, Publication Number 2016-161 (Supersedes 2014-138). OH: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH), 2016
  2. Celano P, Fausel CA, Kennedy EB, et al. Safe handling of hazardous drugs: ASCO standards. J Clin Oncol 2019;37: 598–609.
  3. US Pharmacopeia. General Chapter <800> Hazardous Drugs—Handling in Healthcare Settings
  4. Polovich M, Olsen M. Safe handling of hazardous drugs. 3rd Ed. Oncology Nursing Society, 2018
  5. Dillon LR. Quality control: personal protective equipment for use when handling hazardous drugs. Int J Pharm Compd 2020; 24:30–36.
  6. Makino T, Hasegawa N, Takizawa R, et al. Suggestions for Protecting Breast Cancer Patients Receiving Outpatient Chemotherapy and Their Families Against the Exposure Risk from Salivary Cyclophosphamide. Int J Nurs Clin Pract 2020;7: 320, doi: https://doi.org/10.15344/2394- 4978/2020/320
  7. Gourd E. New drug-transfer device reduces hazardous exposure. Lancet Oncol 2017;18: e312.
  8. Voelcker G. Causes and possibilities to circumvent cyclophosphamide toxicity. Anticancer Drugs doi: 10.1097/CAD.0000000000000912, 2020 Feb 8
  9. Gajski G, Ladeira C, Gerić M, et al. Genotoxicity assessment of a selected cytostatic drug mixture in human lymphocytes: A study based on concentrations relevant for occupational exposure. Environ Res 2018;161: 26–34.
  10. Sessink PJ. Environmental contamination with cytostatic drugs: past, present and future. Saf Consid Oncol Pharm Special Edition 2011